filmov
tv
Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic Cancers
Показать описание
Dr. Skoulidis chats with Terri Conneran, a stage 3 lung cancer patient with a KRAS mutation, about treatment strategies and options. They discuss adagrasib and sotorasib, new clinical trials, and the significance of KRAS G12C, G12D, G12S mutations. Topics covered include STK11, KEAP1, CtDNA, liquid biopsy, stable disease, and combination therapies.
Dr. Ferdinandos Skoulidis, an Associate Professor at The University of Texas MD Anderson Cancer Center, brings his expertise in thoracic/head and neck medical oncology to the conversation. Terri Conneran, a KRAS G12D lung cancer patient of six years, seeks answers to make the best choices for her treatment journey.
The American Association for Cancer Research (AACR.org) organizes an annual research conference. The April 2023 conference featured extensive updates on KRAS mutation data, providing valuable insights for patients and healthcare professionals alike.
Are you KRAS Wild or KRAS Mutant? Don't hesitate to ask your healthcare provider. By understanding your KRAS status, you can make informed decisions about your cancer treatment journey.
Dr. Ferdinandos Skoulidis, an Associate Professor at The University of Texas MD Anderson Cancer Center, brings his expertise in thoracic/head and neck medical oncology to the conversation. Terri Conneran, a KRAS G12D lung cancer patient of six years, seeks answers to make the best choices for her treatment journey.
The American Association for Cancer Research (AACR.org) organizes an annual research conference. The April 2023 conference featured extensive updates on KRAS mutation data, providing valuable insights for patients and healthcare professionals alike.
Are you KRAS Wild or KRAS Mutant? Don't hesitate to ask your healthcare provider. By understanding your KRAS status, you can make informed decisions about your cancer treatment journey.
1:56:56
Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic Cancers
0:58:46
Dr. David Hong on KRAS G12C Inhibitors and the Path Ahead - A Conversation with Terri Conneran
2:02:33
Kicking Cancer's Cancer Expert Series: A Conversation with Dr. Marcelo Negrao and Terri Connera...
1:18:54
Targeting KRAS G12C: Amgen's Breakthrough Treatment - Insights from I-Fen Chang and Terri Conne...
5:15:21
KRAS Kickers Connect, October 1, 2022 (entire event)
0:08:15
This Research Could Change Cancer Treatment Forever
0:05:53
Overcoming Barriers to Clinical Trials
0:03:37
Study shows promise of new anti-KRAS drug for pancreatic cancer
0:02:20
Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial
0:53:11
Focus On: Pancreatic Cancer
0:04:15
Roy S. Herbst, MD, PhD, invites you to the 23rd Annual International Lung Cancer Congress®
0:06:00
Perioperative Keytruda for Early Stage NSCLC-Leading Developments & Current Questions in Lung Ca...
0:39:17
Alive and Kicking: Current and Emerging Strategies to Tackle KRAS-Mutant NSCLC
0:26:36
2020 ACCC Clinical Research Award Winner, Dr. Roy Herbst, Yale Cancer Center
0:06:33
ASCO Daily News 2023 Plenary Update - LBA3: ADAURA
1:01:44
Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
0:04:00
Introducing the 2021 Young Investigator Award Recipient: Christine Lovly, MD, PhD
1:34:16
FDA Patient Listening Session 'Drug Development in Molecular Subsets of Non-Small Cell Lung Can...
1:25:49
Dr Mark Awad, M.D, Ph.D.on KRAS-Driven Cancers and Strategies to Overcome Resistance
0:06:04
ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors
0:04:30
Drugging the Elusive KRAS
1:04:36
Gene Fusions & Other Key Genomic Alterations in Solid Tumors: Optimal Targeted Treatment
0:07:21
Comparative Efficacy of Chemoimmunotherapy v Immunotherapy for 1st-Line Treatment of Advanced NSCLC
1:29:43
November 17, 2021 | Smilow Shares: Lung Cancer Awareness Month
Комментарии